Aerobic exercise and a high capacity for exercise may protect against metabolic dysfunction-associated steatotic liver disease (MASLD), also known as fatty liver disease, by increasing the conversion ...

“djuvant chemoradiation combined with camrelizumab was well tolerated and yielded significantly improved long-term survival,” the researchers wrote.

Chemoradiation combined with immunotherapy significantly boosts survival in patients with resected extrahepatic ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as the ...

In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an ...

Olaparib demonstrated activity in a phase 2 trial of patients who had advanced biliary tract cancer with homologous recombination repair (HRR) mutations. Results from this trial were presented at the ...

Camrelizumab, an investigational immunotherapy, on top of adjuvant capecitabine (Xeloda) and radiotherapy, improved survival ...

Fujifilm Pharma’s liposomal formulation of gemcitabine FF-10832 receives US FDA’s orphan drug designation to treat biliary tract cancer: Cambridge, Massachusetts Wednesday, Ju ...

FDA designates FF-10832 as an orphan drug for biliary tract cancer, promising enhanced treatment options for this aggressive ...

The European Commission (EC) has granted conditional approval to Jazz Pharmaceuticals’ Ziihera (zanidatamab) to treat a ...

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Fujifilm’s FF-10832, an investigational liposomal formulation of gemcitabine, for the treatment of biliary tract ...